Epithelial ovarian cancer in Greece: A retrospective study of 1,791 patients by the hellenic cooperative oncology group (HeCOG)

Anticancer Research

Volumn 29, Issue 2, 2009, Pages 745-751

  Pectasides, D ^a   Papaxoinis, G ^a   Fountzilas, G ^b   Aravantinos, G ^c   Bamias, A ^d   Pavlidis, N ^e   Kalofonos, H P ^f   Timotheadou, E ^b   Samantas, E ^c   Briasoulis, E ^e   Skarlos, D V ^g   Economopoulos, T ^a   Dimopoulos, M A ^d  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c AGII ANARGIRI CANCER HOSPITAL   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^f UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^g METROPOLITAN HOSPITAL   (Greece)

Author keywords

Epithelial ovarian cancer; Prognostic factors; Registry; Retrospective

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; PACLITAXEL; PLATINUM DERIVATIVE;

ABDOMINAL HYSTERECTOMY; ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; DRUG HYPERSENSITIVITY; FEBRILE NEUTROPENIA; FEMALE; GREECE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OMENTECTOMY; OVARIECTOMY; OVARY CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GREECE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 61449127539     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Ozols RF: Update on the management of ovarian cancer. Cancer J 8(Suppl 1): 822-30, 2002.
2. Brun JL, Feyler A, Chêne G, Saurel J, Brun G and Hocké C: Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol 78: 21-27, 2000.
3. Akahira JI, Yoshikawa H, Shimizu Y, Tsunematsu R, Hirakawa T, Kuramoto H, Shiromizu K, Kuzuya K, Kamura T, Kikuchi Y, Kodama S, Yamamoto K and Sato S: Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol 81: 398-403, 2001.
4. Stoeckle E, Paravis P, Floquet A, Thomas L, Tunon de Lara C, Bussières E, Macgrogan G, Picot V and Avril A: Number of residual nodules, better than size, defines optimal surgery in advanced epithelial ovarian cancer. Int J Gynecol Cancer 14: 779-787, 2004.
5. Skírnisdóttir I and Sorbe B: Prognostic factors for surgical outcome and survival in 447 women treated for advanced (FIGO-stages III-IV) epithelial ovarian carcinoma. Int J Oncol 30: 727-734, 2007.
6. Skírnisdóttir I and Sorbe B: Survival and prognostic factors in early-stage epithelial ovarian carcinoma treated with taxane-based adjuvant chemotherapy. Int J Gynecol Cancer 17: 1231-1237, 2007.
7. Winter WE III, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F and McGuire WP: Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25: 3621-3627, 2007.
8. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6, 1996.
9. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B and Pecorelli S: Randomized intergroup trial of cisplatin-paclitaxel vs. cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92: 699-708, 2000.
10. Kjaerbye-Thygesen A, Huusom LD, Frederiksen K and Kjaer SK: Trends in the incidence and mortality of ovarian cancer in Denmark 1978-2002. Comparison with other Nordic countries. Acta Obstet Gynecol Scand 84: 1006-1012, 2005.
11. Quirk JT and Natarajan N: Ovarian cancer incidence in the United States, 1992-1999. Gynecol Oncol 97: 519-523, 2005.
12. Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS, Berek JS and Osann K: Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 108: 521-528, 2006.
13. Tetsche MS, Dethlefsen C, Pedersen L, Sorensen HT and Norgaard M: The impact of comorbidity and stage on ovarian cancer mortality: a nationwide Danish cohort study. BMC Cancer 8: 31, 2008.
14. Vernooij F, Heintz AP, Witteveen PO, van der Heiden-van der Loo M, Coebergh JW and van der Graaf Y: Specialized care and survival of ovarian cancer patients in the Netherlands: nationwide cohort study. J Natl Cancer Inst 100: 399-406, 2008.
15. Curtin JP, Malik R, Venkatraman ES, Barakat RR and Hoskins WJ: Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol 64: 9-12, 1997.
16. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS and Karlan BY: Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 72: 278-287, 1999.
17. Naik R, Nordin A, Cross PA, Hemming D, de Barros Lopes A and Monaghan JM: Risk factors in stage III epithelial ovarian cancer: previous sterilisation is an adverse independent prognostic indicator. Eur J Gynaecol Oncol 21: 357-361, 2000.
18. Oksefjell H, Sandstad B and Trope C: Improved survival for stage IIIC ovarian cancer patients treated at the Norwegian Radium Hospital between 1984 and 2001. Eur J Gynaecol Oncol 28: 256-262, 2007.
19. Winter WE III, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F and McGuire WP: Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 26: 83-89, 2008.
20. Chi DS, Liao JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D and Hoskins WJ: Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 82: 532-537, 2001.
21. Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, de Swart CA, Hirsch FR, Lund B and van Houwelingen HC: Exploratory phase III study of paclitaxel and cisplatin vs. paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18: 3084-3092, 2000.
22. du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W and Pfisterer J; Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group: A randomized clinical trial of cisplatin/paclitaxel vi. carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95: 1320-1329, 2003.
23. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A and Kaye SB; Scottish Gynaecological Cancer Trials Group: Phase III randomized trial of docetaxel-carboplatin vs. paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96: 1682-1691, 2004.
24. Aravantinos G, Fountzilas G, Kosmidis P, Dimopoulos MA, Stathopoulos GP, Pavlidis N, Bafaloukos D, Papadimitriou C, Karpathios S, Georgoulias V, Papakostas P, Kalofonos HP, Grimani E and Skarlos DV; Hellenic Cooperative Oncology Group: Paclitaxel plus carboplatin vs. paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study. Ann Oncol 16: 1116-1122, 2005.
25. Pectasides D, Fountzilas G, Aravantinos G, Bamias A, Kalofonos HP, Skarlos D, Briasoulis E, Konstantara A, Economopoulos T and Dimopoulos MA: Epithelial ovarian carcinoma in younger vi. older women: is age an independent prognostic factor? The Hellenic Oncology Cooperative Group experience. Int J Gynecol Cancer 77: 1003-1010, 2007.
26. Pectasides D, Fountzilas G, Aravantinos G, Kalofonos HP, Efstathiou E, Salamalekis E, Farmakis D, Skarlos D, Briasoulis E, Economopoulos T and Dimopoulos MA: Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 97: 436-441, 2005.
27. Pectasides D, Pectasides E, Psyrri A and Economopoulos T: Treatment issues in clear cell carcinoma of the ovary: a different entity? Oncologist 11: 1089-1094, 2006.
28. Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, Skarlos D, Pavlidis N, Economopoulos T and Dimopoulos MA: Advanced stage clear cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 102: 285-291, 2006.